Table 1.
Study assessments schedule
| Assessments | Study visits | ||
|---|---|---|---|
| Screening | Baseline | 6-monthly (until 2 years from baseline) | |
| Informed consent | ✓ | ||
| Demographics characteristics | ✓ | ||
| Systolic and diastolic blood pressuresa | ✓ | ✓ | ✓ |
| Current blood pressure medications | ✓ | ||
| Socioeconomic characteristics | ✓ | ||
| Medical history | ✓ | ||
| Concomitant medications | ✓ | ✓ | |
| Family medical history | ✓ | ||
| Tobacco smoking status | ✓ | ✓ | |
| International physical activity questionnaire | ✓ | ✓ | |
| Dietary questionnaire | ✓ | ✓ | |
| EQ-5D-5L questionnaire | ✓ | ✓b | |
| MMAS-8 for antihypertensive medication adherence | ✓ | ✓ | |
| MMAS-8 for statins adherence | ✓ | ||
| Adiposity measures (BMI, waist circumference) | ✓ | ✓ | |
| Laboratory tests | ✓ | ✓b | |
| Serum creatinine | |||
| Fasting blood glucose | |||
| Total cholesterol | |||
| High density lipoprotein cholesterol | |||
| Low density lipoprotein cholesterol | |||
| Triglycerides | |||
| Urine spot albumin | |||
| Urine spot sodium | |||
| Urine spot creatinine | |||
| Adverse/serious adverse events | ✓ | ✓ | |
| Death | ✓ | ||
aOnly measurements taken by independent assessors who will be masked to randomization will be used for the analysis
bTo be assessed only at final follow-up visit